<p>Compugen Ltd. announced an amendment to its exclusive license agreement with AstraZeneca to monetize a portion of its future royalty interest in rilvegostomig. Under the updated terms, Compugen will receive an upfront payment of $65 million and may receive an additional $25 million upon reaching the next milestone related to BLA acceptance. The total potential value of the transaction is up to $90 million. Compugen will retain the majority of its future royalties and remains eligible for tiered royalties of up to mid-single digits on future sales, as well as potential future regulatory and commercial milestone payments of up to $195 million. The transaction is intended to extend Compugen’s cash runway into 2029 and support its immuno-oncology pipeline development. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compugen Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO49605) on December 17, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

Compugen Sells Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million